Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York.

Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer, Richard Kenney, M.D., Chief Medical Officer, and Jay Cross, Chief Financial Officer, will be presenting on May 15th. Interested parties can register to attend here. Members of the Sonnet BioTherapeutics management team will also be holding one-on-one investor meetings throughout the day.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as F_HAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s F_HAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F_HAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

About EF Hutton LLC

EF Hutton LLC is an investment bank headquartered in New York, NY, which provides strategic advisory and financing solutions to middle market and emerging growth companies. EF Hutton has a proven track record of offering superior strategic advisory to clients across the globe in any sector, with unique access to capital from the USA, Asia, Europe, UAE, and Latin America.

EF Hutton is a leader on Wall Street, having raised over $16 billion in capital across more than 270 transactions through various product types. Since 2022, by deal count, the firm has been #1 in US IPO issuance and #1 in SPAC issuance, per Bloomberg and SPAC Insider. EF Hutton is one of the most active investment banks in the middle of the market space. For more information, please visit efhutton.com.

Sonnet BioTherapeutics Investor Contact:
Jack Yauch
Solebury Strategic Communications
862-754-1024
jyauch@soleburystrat.com

SOURCE: Sonnet BioTherapeutics, Inc.

View the original press release on accesswire.com